Ravidasvir

Overview

Ravidasvir is under investigation in clinical trial NCT02961426 (Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection).

Indication

联合利托那韦强化的达诺瑞韦钠片和利巴韦林，用于治疗初治的基因1b型慢性丙型肝炎病毒感染的非肝硬化成人患者，不得作为单药治疗。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C	2021/05/13	NCT04885855	Phase 2	Completed	Muhammad Radzi Abu Hassan
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)	2021/02/09	NCT04745351	Phase 3	Terminated	Gilead Sciences
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting	2020/08/06	NCT04501952	Phase 3	Terminated	Gilead Sciences
A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers	2020/04/24	NCT04358523	Phase 1	Completed	Ascletis Pharmaceuticals Co., Ltd.
A Phase 1 Bioequivalence Study of a Test Tablet Formulation of Ravidasvir With the Reference Tablet Formulation of Ravidasvir Study	2018/07/26	NCT03602300	Phase 1	Completed	Drugs for Neglected Diseases
A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China	2018/02/13	NCT03430830	Phase 1	Completed	Ascletis Pharmaceuticals Co., Ltd.
Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.	2017/12/05	NCT03362814	Phase 2	Completed	Ascletis Pharmaceuticals Co., Ltd.
Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China	2017/09/20	NCT03288636	Phase 1	Completed	Ascletis Pharmaceuticals Co., Ltd.
Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan	2017/01/13	NCT03020095	Phase 2	Completed	Ascletis Pharmaceuticals Co., Ltd.
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China	2017/01/13	NCT03020134	Phase 1	Completed	Ascletis Pharmaceuticals Co., Ltd.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Federal Circuit Ruling Opens New Patent Challenge Avenue for Life Sciences Companies

2 months ago

The U.S. Court of Appeals for the Federal Circuit's decision in Xencor Inc. case provides drugmakers with a new strategy to challenge patents by focusing on inadequate written descriptions in Jepson claims.

Taiwan Approves Chugai's PiaSky as First Subcutaneous Treatment for Paroxysmal Nocturnal Hemoglobinuria

2 months ago

Taiwan FDA has granted orphan drug approval for PiaSky, making it the first subcutaneous treatment for paroxysmal nocturnal hemoglobinuria (PNH) available in Taiwan for patients 13 years and older.

Astellas to Present New IZERVAY Data on Geographic Atrophy at Major Ophthalmology Congresses

3 months ago

Astellas will showcase nine abstracts on IZERVAY™ (avacincaptad pegol) at the ARVO and RWC ophthalmology meetings in May 2025, including two oral presentations on ellipsoid zone integrity and its relationship to vision outcomes.

Novartis's Fabhalta Rapidly Reshapes PNH Treatment Landscape as Biosimilars Loom

4 months ago

Fabhalta (Novartis) has gained significant market share in just 15 months since its December 2023 launch, with physician consideration for first-line use doubling year-over-year in the PNH treatment space.

Rallybio Advances FNAIT Candidate RLYB212 to Phase 2 Trial, Eyes Expanded Market

6 months ago

• Rallybio is set to begin a Phase 2 trial for RLYB212 in Q2 2025, targeting Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) prevention, with interim data expected in Q3. • Recent epidemiological analysis has expanded the estimated market for FNAIT treatment to over 30,000 at-risk pregnancies annually in the U.S. and EU. • The company is also progressing its C5 inhibitor RLYB116 and ENPP1 inhibitor REV102, with studies planned to broaden its therapeutic pipeline. • Rallybio's current cash reserves of $89 million are projected to sustain operations until mid-2026, supporting the advancement of its clinical programs.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access